Gene Therapy from A to Z. Chances and Risks of Gene Therapy: Ethical Considerations

Course information

Teaching objective
This course gives an overview of the historical development and an outlook on the future of gene and cell therapy. Principles of somatic and germline gene therapies as well as CAR-T-cell therapy are explained. Legal aspects and ethical issues such as risks, costs and societal implications are discussed.

Primary target group:
Physicians of all disciplines

Scientific director/lecturer:
Prof. Dr. med. Dr. phil. Nikola Biller-Andorno
Director Institute of Biomedical Ethics and History of Medicine (IBME)
University of Zurich

Lecturer:
Dr. sc. nat. Daniela Suter
Managing Director
GEN SUISSE

DFP-points:
For correctly answering the multiple-choice questions 1 point is awarded for the Diploma Continuing Education Programme of the Austrian Medical Association.

Medical speciality:
all disciplines

Lecture Board:
Ao. Univ.-Prof. Dr. med. univ. Christoph Male-Dressler
Klinische Abteilung für Pädiatrische Kardiologie
Medizinische Universität Wien

Univ.- Prof. Dr. Wolfgang Högler
Universitätsklinik für Kinder- und Jugendheilkunde
Kepler Universitätsklinikum, Linz

Medical training provider:
Gesellschaft der Ärzte

Organisation:
Universimed Cross Media Content GmbH

Cost:
This course is provided to you free of charge.

Disclosure Statement:
All persons presenting at this course or contributing to the content have been asked to disclose any conflicts of interest that may exist that could be associated with influencing the course content.

Sponsor:
Pfizer Corporation Austria Ges.m.b.H.

Valid until:
September 2024

_{PP-UNP-AUT-0099/06.2022}